Review of current treatment practices for carcinoma of the head and neck
暂无分享,去创建一个
A. Mundt | J. Epstein | M. Yao | K. Pytynia | B. Knab | L. Feldman | Bijal J Modi
[1] R. Weichselbaum,et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. , 2005, International journal of radiation oncology, biology, physics.
[2] R. Ewers,et al. Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients. , 2005, International journal of oral and maxillofacial surgery.
[3] D. Raben,et al. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. , 2004, Oncology.
[4] D. Haraf,et al. Reirradiation of recurrent head and neck cancers with curative intent. , 2004, Seminars in oncology.
[5] A. Paccagnella,et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. , 2004, Journal of the National Cancer Institute.
[6] A. Forastiere. Is there a new role for induction chemotherapy in the treatment of head and neck cancer? , 2004, Journal of the National Cancer Institute.
[7] Christopher U. Jones,et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Baselga,et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Gorlia,et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Weichselbaum,et al. Twice-daily re-irradiation of recurrent and second primary head and neck cancer with gemcitabine, paclitaxel and fluorouracil chemoradiotherapy. , 2004, Journal of Clinical Oncology.
[11] S. Dakhil,et al. A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head & neck (SCCHN): A Southwest Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Rojas,et al. Management of cancer of the head and neck--a cocktail with your PORT? , 2004, The New England journal of medicine.
[13] Jacques Bernier,et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.
[14] J. Jacobs,et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.
[15] E. Vokes,et al. The expanding role of systemic therapy in head and neck cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Caponigro,et al. New cytotoxic and molecular-targeted therapies of head and neck tumors , 2004, Current opinion in oncology.
[17] G. Weinstein,et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. , 2004, International journal of radiation oncology, biology, physics.
[18] E. Vokes,et al. Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer , 2004, Head & neck.
[19] N. Slevin,et al. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] J. Ochs. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. , 2004, International journal of radiation oncology, biology, physics.
[21] R. Weichselbaum,et al. Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer , 2003 .
[22] R. Weber,et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.
[23] L. Rybicki,et al. Who merits a neck dissection after definitive chemoradiotherapy for N2–N3 squamous cell head and neck cancer? , 2003, Head & neck.
[24] L. Dawson,et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. , 2003, International journal of radiation oncology, biology, physics.
[25] M. Atkins,et al. Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment , 2003 .
[26] R. Mohan,et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. , 2003, International journal of radiation oncology, biology, physics.
[27] E. Vokes,et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Baselga,et al. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] Daniel A Low,et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. , 2003, International journal of radiation oncology, biology, physics.
[30] A. Rademaker,et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] C. Haie-meder,et al. Brachytherapy for T1-T2 floor-of-the-mouth cancers: the Gustave-Roussy Institute experience. , 2002, International journal of radiation oncology, biology, physics.
[32] C. Perez,et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[33] P. Xia,et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.
[34] S. Stringer,et al. Carcinoma of the supraglottic larynx: Treatment results with radiotherapy alone or with planned neck dissection , 2001, Head & neck.
[35] W. Mendenhall,et al. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Bourhis,et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma , 2001, Cancer.
[37] E. Lamont,et al. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. , 2001, The Lancet. Oncology.
[38] S. Stringer,et al. Organ preservation with radiotherapy for T1‐T2 carcinoma of the pyriform sinus , 2001, Head & neck.
[39] B. Murphy,et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] D. Shin,et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] S. Lippman,et al. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. , 2001, Archives of otolaryngology--head & neck surgery.
[42] B. Coche-Déquéant,et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma , 2000, British Journal of Cancer.
[43] R. Weichselbaum,et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. , 2000, Archives of otolaryngology--head & neck surgery.
[44] S. Stringer,et al. Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] A. Carvalho,et al. Natural history of untreated head and neck cancer. , 2000, European journal of cancer.
[46] B. Jeremic,et al. Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial , 2000 .
[47] J. Bourhis,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.
[48] W. Russell,et al. Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity* , 2000, The Journal of Biological Chemistry.
[49] K. Chao,et al. Stage I (t1 N0 M0) squamous cell carcinoma of the laryngeal glottis: Therapeutic results and voice preservation , 1999, Head & neck.
[50] Bruce H. Haughey,et al. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation. , 1999 .
[51] E K Rowinsky,et al. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] H. Tideman. CARCINOMA of the head and neck. , 1999, Maryland state medical journal.
[53] J. Bourhis,et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] D. Brasnu,et al. Neo‐adjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidopexy for advanced endolaryngeal carcinoma classified as T3–T4: 5‐year oncologic results , 1998, Head & neck.
[55] K. Ang,et al. Precisely defining high‐risk operable head and neck tumors based on rtog #85‐03 and #88‐24: Targets for postoperative radiochemotherapy? , 1998, Head & neck.
[56] R. Spiro,et al. A prospective phase ii trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck , 1998, Head & neck.
[57] A. Huang,et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.
[58] T. Wendt,et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Hanauske,et al. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] L. Bastholt,et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[61] M. Secic,et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer , 1997, Head & neck.
[62] B. Kavanagh,et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation , 1997, Oncogene.
[63] J. Quivey,et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. , 1997, International journal of radiation oncology, biology, physics.
[64] L. Collette,et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.
[65] E. Strong,et al. 21 Long term results of primary radiation therapy for squamous cancer of the base of tongue , 1996 .
[66] W. Curran,et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. , 1995, International journal of radiation oncology, biology, physics.
[67] M. August,et al. Early carcinoma of the oral cavity: a conservative approach with radiation therapy. , 1995, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[68] L. Eapen,et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] M. Zelefsky,et al. Performance status after treatment for squamous cell cancer of the base of tongue--a comparison of primary radiation therapy versus primary surgery. , 1994, International journal of radiation oncology, biology, physics.
[70] S. Stringer,et al. Carcinoma of the oral tongue: A comparison of results and complications of treatment with radiotherapy and/or surgery , 1994, Head & neck.
[71] K. Valerie,et al. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. , 1994, International journal of radiation oncology, biology, physics.
[72] M. Piccart,et al. Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck , 1994 .
[73] G. Browman,et al. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. , 1994, Seminars in oncology.
[74] A. Paccagnella,et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. , 1994, Journal of the National Cancer Institute.
[75] S. Stringer,et al. Radiotherapy alone or combined with neck dissection for T1-T2 carcinoma of the pyriform sinus: an alternative to conservation surgery. , 1993, International journal of radiation oncology, biology, physics.
[76] A. Forastiere. Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. , 1993, Seminars in oncology.
[77] R. Tsang,et al. Squamous cell carcinoma of the lip: analysis of the Princess Margaret Hospital experience. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[78] L. Hutchins,et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] N. Hayward,et al. Analysis of gene amplification in head‐and‐neck squamous‐cell carcinomas , 1991, International journal of cancer.
[80] W. Hong,et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. , 1991, The New England journal of medicine.
[81] J E Medina,et al. Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology. , 1991, Archives of otolaryngology--head & neck surgery.
[82] J. Crook,et al. Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue and floor of mouth with interstitial iridium-192. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[83] J. Crook,et al. Iridium 192 implantation of T1 and T2 carcinomas of the mobile tongue. , 1990, International journal of radiation oncology, biology, physics.
[84] L. Harrison,et al. Prospective computer-assisted voice analysis for patients with early stage glottic cancer: a preliminary report of the functional result of laryngeal irradiation. , 1990, International journal of radiation oncology, biology, physics.
[85] W. Fee,et al. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the northern California oncology group , 1987, Cancer.
[86] F. Baillet,et al. A retrospective study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone. , 1987, International journal of radiation oncology, biology, physics.
[87] W. Mendenhall,et al. Carcinoma of the soft palate treated with irradiation: analysis of results and complications. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[88] F. Demard,et al. Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. , 1986, British Journal of Cancer.
[89] J. Horiot,et al. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. , 1986, International journal of radiation oncology, biology, physics.
[90] J. Jacobs,et al. Improved complete response rate and survival in advanced head and neck cancer after three‐course induction therapy with 120‐hour 5‐FU infusion and cisplatin , 1985, Cancer.
[91] M. Hidalgo,et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[93] E. Vokes,et al. Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] J. Wilson,et al. Cisplatinum and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial , 2004, Cancer Chemotherapy and Pharmacology.
[95] M. al-Sarraf. Chemotherapeutic management of head and neck cancer , 2004, Cancer and Metastasis Reviews.
[96] J. Ensley,et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] A. Ullrich,et al. Receptor tyrosine kinases as targets for anticancer drugs. , 2002, Trends in molecular medicine.
[98] B. Burtness,et al. Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC) , 2002 .
[99] J. Baselga,et al. ZD1839 ('Iressa') as an anticancer agent. , 2000, Drugs.
[100] R Mohan,et al. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. , 2000, International journal of radiation oncology, biology, physics.
[101] A. Garden,et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. , 2000, International journal of radiation oncology, biology, physics.
[102] G. Calais,et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. , 1999, Journal of the National Cancer Institute.
[103] Jay S. Cooper,et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 , 1999 .
[104] G. Catimel. Head and neck cancer: guidelines for chemotherapy. , 1996, Drugs.
[105] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.
[106] Z. Petrovich,et al. Carcinoma of the lip and selected sites of head and neck skin. A clinical study of 896 patients. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[107] J. Medina,et al. Treatment of choice for squamous carcinoma of the tonsillar fossa. , 1985, Head & neck surgery.